At Ironwood, we are committed to finding new treatments for patients living with GI diseases
Our vision is clear: bring new, differentiated therapies to the millions of patients who live with GI diseases.
Building on a strong, decades-long foundation, the next leg of our journey continues with three innovative assets. Our in-market product, LINZESS® (linaclotide), discovered in-house, is the branded prescription market leader in its class.
We believe we have what it takes to achieve our vision and we’re all in. Together, we’re paving a path to long-term success.
I am excited about the opportunity to be GI-focused and to bring exciting new therapies to our trusted GI community.”
Robin May, Clinical Sales Specialist, Jefferson City, MOEveryone at Ironwood is a true owner of the company. The ownership mindset extends beyond the home office and out into the field sales organization. Being an owner, I am interested in the entire company doing well, not just myself or my team.”
Stacy Pokrywka, Regional Sales Manager, Great LakesCopyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved
LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.